

AMICUS COMPLETES FIFTEEN DEALS IN 2018

PRESS RELEASE NO. 21

January 2nd, 2019

Amicus SA of Switzerland announced today that it had signed 15 deals for new territories and / or products in the course of 2018.

Baar, Switzerland, January 2nd, 2019: Amicus S.A. revealed that it had completed fifteen licensing, purchase or agency / representation distribution contracts in the 2018 calendar year:

1. With **Bristol-Myers Squibb** to include the new territories of Bulgaria and Slovakia for the entire BMS Rx portfolio including Opdivo and Yervoy;
2. With **Amgen** for the territories of Bosnia, Macedonia, Montenegro and Serbia for Amgen's entire portfolio including Aranesp and Kyprolis;
3. With **Laboratoires Expanscience** to include the new territories of the 3 Baltic republics as well as both Croatia and Slovenia for its innovative line of skincare products for mothers and babies marketed under the Mustela umbrella brand;
4. With **Medis and Polfarma / FarmaProjects** for rights to eight differentiated medicines that will be launched in the course of 2019-20 in several Amicus territories;
5. With **Abiogen** of Italy for rights to its family of oral Vitamin D prescription products for several territories;
6. With **Contura** of the UK to represent its injectable medical device for female stress urinary incontinence, Bulkamid (previously distributed by J&J) in Bosnia, Croatia, Serbia and Slovenia;
7. With **Bausch Healthcare Companies** to represent several of its branded medicines (Rx and OTC, including Cardiopirin, Monopril, Rapidol and Tamsol) in Bosnia;
8. With **Fresenius** to represent its pharmaceutical portfolio in the territory of Bosnia & Herzegovina;
9. With **Norgine** to include the new territory of Bosnia for its market-leading medicine Moviprep, which is used prior to any clinical procedure requiring a clean bowel, including endoscopy or radiology;
10. With **Natumin Pharma** of Sweden for rights to its product Ecomer for the territory of Serbia;
11. With **Panacea Biotec** for the territories of Serbia and rest of non-EU West Balkans for its Nimulid brands, the leading nimesulide family of products in the region;

12. With **Laboratoires Biofar** of France for its family of effervescent minerals and vitamin supplements in Serbia;
13. With **Efarmes** of Spain for rights in Serbia and Montenegro to its second-generation oral steroid, deflazacort;
14. With **Asahi Kasei** of Japan to represent its family of high-performance dialysers in the territory of Serbia;
15. With **Genexo** of Poland for rights (including TM purchases) to its food supplement products Multilac and Citri-Mg for the territories of non-EU West Balkans.

“I am very pleased with the continuing strong deal flow we are experiencing here at Amicus,” commented Amicus CEO Jean-Michel Lespinasse. “In particular, we’re gratified to see tangible evidence that several of our existing clients are well-enough satisfied with Amicus’ execution, probity and passion to choose to broaden their relationships with us -- by granting to Amicus additional territories and new products. Indeed, as we go into the new year of 2019, I would like to take the opportunity to express our thanks and appreciation to all of our partners for affording Amicus the privilege of representing their healthcare products, and for their continuing faith in our company.

“Finally,” continued Lespinasse, “I would be remiss if I didn’t highlight the numerous BD breakthroughs engineered in 2018 by our Belgrade office, where Regional BD Head Ivan Pertot, working closely with Predrag Lukic, our non-EU West Balkan Regional GM, have consummated (amongst many of the initiatives listed above) two landmark deals for our company – of actually purchasing long-term rights or outright ownership of products with sales of a million Euros or more. In the the Natumin Pharma deal, for instance, Amicus secured long term rights for the shark liver oil product Ecomer, and in the Genexo deal, Amicus bought both the TMs and local registrations of the probiotic Multilac and the mineral supplement Ci-Tri-Mag. It is my sincere hope that we will see similar initiatives in a broader geography in the next years.”

About Amicus S.A.

Amicus now operates fully-owned subsidiaries across all of Central and Eastern Europe, with the exception of Russia and the CIS countries. Sales in 2018 exceeded 70 million Euros and in 2019 should top 100 million Euros. Established in 2014, Amicus has gathered outstanding pharmaceutical, rare disease, medical device and OTC / consumer healthcare talent under one roof. The company specializes in representing research-based pharmaceutical, orphan, medical equipment and self-care brands.

For more info about Amicus, please visit: www.amicuspharma.eu

Contact:

Maja Boskovic, Public Affairs Officer, Amicus

Maja.Boskovic@amicuspharma.eu, Tel: +381 11 4426 321